OskoTec Exports Autoimmune Disease Drug Technology to Agios in $1 Billion Deal
Transfer of Global Development and Commercialization Rights for Cevidoplenib
Up to $665 Million Including $25 Million Upfront Payment and Milestone Payments
OskoTec announced on June 1 that it has signed a technology transfer agreement with the U.S. biopharmaceutical company Agios for the autoimmune disease treatment candidate, cevidoplenib.
Under the agreement, OskoTec will transfer the exclusive clinical development and global commercialization rights of cevidoplenib to Agios. OskoTec will receive a non-refundable upfront payment of 25 million dollars (approximately 37.5 billion won). Including development, regulatory, and commercialization milestones, the company could receive up to 665 million dollars (approximately 1 trillion won). OskoTec will also receive separate royalties after the product is commercialized.
Cevidoplenib is an oral SYK (Spleen Tyrosine Kinase) inhibitor jointly developed by OskoTec and Genosco. It has completed global Phase 2 clinical trials targeting immune thrombocytopenia (ITP) and rheumatoid arthritis (RA), and in 2024, it was designated as an orphan drug for ITP treatment by the U.S. Food and Drug Administration (FDA).
This candidate works by selectively inhibiting SYK, which is expressed in B cells and macrophages, thereby blocking the inflammatory response caused by autoantibodies. Its safety and efficacy were confirmed in the Phase 2 clinical trial for ITP completed in 2023.
The upfront payment and milestone payments under this agreement will be distributed between OskoTec and Genosco at a ratio of 75% to 25%, respectively, according to their 2016 agreement.
Agios specializes in the development and commercialization of treatments for rare diseases. The company owns mitapivat, a treatment for red blood cell metabolic disorders, which has been approved in the United States, Europe, and other regions for indications such as thalassemia and pyruvate kinase (PK) deficiency.
OskoTec plans to strengthen its research and development strategy focusing on anti-resistance anticancer drugs, using this technology export as momentum. In March, the company signed a collaboration agreement with U.S.-based Yatiri Bio for the joint development of denpibontinib, a candidate treatment for acute myeloid leukemia (AML).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Tae Young Yoon, CEO of OskoTec, stated, "We believe Agios, with its expertise in rare blood disorders, is the optimal partner to maximize the value of cevidoplenib," adding, "We hope it will grow into a global new drug."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.